ENDO 2026
Poster Access
Long-term safety and efficacy of CAM2029 in patients with acromegaly: results from the ACROINNOVA 2 open-label extension
Long-term CAM2029 octreotide depot maintains biochemical and symptom control in acromegaly across a 4-week dosing interval and during intervals >28 days: data from the ACROINNOVA 2 trial
Effect of CAM2029 on long-term biochemical and symptom control in patients with acromegaly and IGF-I ≤2×ULN according to prior injectable somatostatin receptor ligand dose: results from ACROINNOVA 2
